The state of California currently has 62 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up
NCT05586204
Recruiting
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages affect the take-up of bivalent COVID-19 booster. The investigators will test the impact of sending text reminders as well as the importance of elevating vaccination intentions, facilitating action, and their combination.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2022
Locations: UCLA Health Department of Medicine, Quality Office, Los Angeles, California
Conditions: COVID-19, Vaccines
Register for Updates
Effects of Prompt to Bundle COVID-19 Booster and Flu Shot
NCT05586165
Recruiting
This randomized controlled trial investigates whether text-based reminders can increase the bivalent COVID-19 booster uptake and whether text-based reminders that mention the opportunity to bundle the COVID-19 booster with the flu shot within the same appointment can increase take-up of both the COVID-19 booster and the flu vaccine.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/04/2022
Locations: UCLA Health Department of Medicine, Quality Office, Los Angeles, California
Conditions: COVID-19, Vaccines
Register for Updates
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
NCT05280717
Recruiting
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy participants aged 18 to 65 years. The study will be conducted in three parts (Part A, an optional Part B and Part C).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/02/2022
Locations: Investigative Site, Riverside, California
Conditions: Covid19
Register for Updates
IMM-BCP-01 in Mild to Moderate COVID-19
NCT05429021
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
08/11/2022
Locations: Ark Clinical Research, Long Beach, California
Conditions: SARS-CoV2 Infection, COVID-19
Register for Updates
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
NCT04780685
Recruiting
This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/07/2022
Locations: Providence Medical Foundation, Fullerton, California +1 locations
Conditions: Covid19
Register for Updates
Long Haul COVID Rehabilitation & Recovery Research Program
NCT05398692
Recruiting
The purpose of the study is to assess the physiologic, immunologic, and mental health effects of a rehabilitation program on patients with Long Haul COVID (LHC).
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/28/2022
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Long Haul COVID or Post Acute Sequella of COVID - PASC (U09.9)
Register for Updates
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
NCT05228717
Recruiting
This study seeks to define the ultrasound profile of patients with COVID-19, and document the progression of these ultrasound findings to develop prognostication and clinical decision instruments that can help guide management of patient with COVID-19. Primary aims include the development of ARDS, refractory hypoxemia, acute cardiac injury, pulmonary embolism, pneumothorax or death. Secondary aims include potential change in CT and plain film utilization given the use of POCUS, as well as emerge... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2022
Locations: UCLA-Ronald Reagan, Los Angeles, California +1 locations
Conditions: Lung Injury, ARDS, Acute Cardiac Event, Covid19, Ultrasound, Hypoxemia, Acute Respiratory Distress Syndrome
Register for Updates
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
NCT05060991
Recruiting
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction impro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2022
Locations: University of California, Davis, Sacramento, California
Conditions: COVID-19, Immunosuppression, Vaccine Response Impaired
Register for Updates
POC Study to Evaluate the Performance of the AcuVid COVID-19 Rapid Antigen Saliva Test
NCT05119530
Recruiting
The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect. The AcuVid COVID-19 Rapid Antigen Saliva Test performance will be compared to a high sensitivity FDA EUA approved RT-PCR COVID-19 test. Nasopharyngeal (for RT... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
12/21/2021
Locations: Covid Clinic Inc., Modesto, California
Conditions: COVID-19
Register for Updates
Single-Blind Study of STAT-205 in Mild COVID-19
NCT04708327
Recruiting
This is a randomized, single blind, study. Males and females meeting inclusion criteria who have symptoms of mild COVID-19 and in whom a positive PCR result for SARS-CoV-2 is obtained may be enrolled to the study treatment within 72 hours of the positive PCR result. Eligible patients are those considered to be at high risk for COVID-19 disease progression. This includes patients ≥ 65 years of age or with any one or more of certain medical conditions including: cancer, COPD, cardiovascular diseas... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2021
Locations: Loma Linda University, Loma Linda, California
Conditions: COVID-19
Register for Updates
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
NCT05149300
Recruiting
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety and tolerability of SC or single administration of casirivimab+imdevimab To assess the occurrence of grade ≥3 injection site reactions and grade ≥3 hypersensitivity reactions, in participants treated with SC doses of casirivimab+imdevimab To assess the immunogenicity o... Read More
Gender:
All
Ages:
12 years and below
Trial Updated:
12/06/2021
Locations: Advanced Research Center, Inc, Anaheim, California
Conditions: COVID-19
Register for Updates
Communities Fighting COVID-19!
NCT05148936
Recruiting
To create and evaluate effective COVID-19 testing uptake strategies that focus on underserved individuals who are exposed but have not accessed testing, and underserved individuals who are not routinely tested because they are unaware of their exposure or risk status in order to increase testing among these populations and reduce Covid-19 related disparities.
Gender:
All
Ages:
Between 6 years and 120 years
Trial Updated:
12/03/2021
Locations: Contact Households, San Diego, California
Conditions: Covid19
Register for Updates